WO2014096440A3 - Albumin composition for preventing and/or reducing formation of peptide fibrils - Google Patents

Albumin composition for preventing and/or reducing formation of peptide fibrils Download PDF

Info

Publication number
WO2014096440A3
WO2014096440A3 PCT/EP2013/077869 EP2013077869W WO2014096440A3 WO 2014096440 A3 WO2014096440 A3 WO 2014096440A3 EP 2013077869 W EP2013077869 W EP 2013077869W WO 2014096440 A3 WO2014096440 A3 WO 2014096440A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
reducing formation
albumin composition
peptide fibrils
peptide
Prior art date
Application number
PCT/EP2013/077869
Other languages
French (fr)
Other versions
WO2014096440A2 (en
Inventor
Jens Thostrup BUKRINSKI
Mette-Marie List JENSEN
Sachin DUBEY
Morten Jonas Maltesen
Birgitte Andersen
Original Assignee
Novozymes Biopharma Dk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Biopharma Dk A/S filed Critical Novozymes Biopharma Dk A/S
Publication of WO2014096440A2 publication Critical patent/WO2014096440A2/en
Publication of WO2014096440A3 publication Critical patent/WO2014096440A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention concerns compositions comprising highly purified albumin suitable for preventing and/or reducing of peptide fibrillation.
PCT/EP2013/077869 2012-12-21 2013-12-20 Composition WO2014096440A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12198965 2012-12-21
EP12198965.1 2012-12-21

Publications (2)

Publication Number Publication Date
WO2014096440A2 WO2014096440A2 (en) 2014-06-26
WO2014096440A3 true WO2014096440A3 (en) 2014-08-14

Family

ID=49880802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/077869 WO2014096440A2 (en) 2012-12-21 2013-12-20 Composition

Country Status (1)

Country Link
WO (1) WO2014096440A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107583039A (en) 2012-01-09 2018-01-16 阿道恰公司 PH is 7 and the Injectable solution at least containing the PI basal insulins for being 5.8 to 8.5 and substitution copolymerization (amino acid)
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
KR20190025905A (en) 2016-06-07 2019-03-12 아도시아 Compositions in the form of injectable aqueous solutions comprising human glucagon and statistical copolyamino acids
FR3072875B1 (en) * 2017-10-31 2020-11-06 Adocia COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
FR3079414B1 (en) * 2018-03-27 2020-05-01 Adocia COMPOSITION COMPRISING A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
WO2019086559A1 (en) * 2017-10-31 2019-05-09 Adocia Composition comprising a glp-2 receptor agonist and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals
FR3083087A1 (en) 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
BR112020011484A2 (en) 2017-12-07 2020-11-17 Adocia compositions in the form of an injectable aquatic solution comprising human glucagon and a copolyamino acid
US10987426B2 (en) 2017-12-07 2021-04-27 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
WO2019110837A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
WO2019110838A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
FR3067247A1 (en) 2018-06-07 2018-12-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
BR112022006546A2 (en) 2019-10-07 2022-08-30 Kallyope Inc GPR119 AGONISTS
KR20230012597A (en) 2020-05-19 2023-01-26 칼리오페, 인크. AMPK activator
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019260A1 (en) * 1991-05-07 1992-11-12 Tomas Moks Peptide hormone solution
WO1999047160A1 (en) * 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
WO2003066681A1 (en) * 2002-02-05 2003-08-14 Delta Biotechnology Limited Stabilization of protein preparations
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
WO2005058958A2 (en) * 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
WO2006128083A2 (en) * 2005-05-25 2006-11-30 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019260A1 (en) * 1991-05-07 1992-11-12 Tomas Moks Peptide hormone solution
WO1999047160A1 (en) * 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
WO2003066681A1 (en) * 2002-02-05 2003-08-14 Delta Biotechnology Limited Stabilization of protein preparations
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
WO2005058958A2 (en) * 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
WO2006128083A2 (en) * 2005-05-25 2006-11-30 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664 - 1669, XP002201014, ISSN: 0022-2623, DOI: 10.1021/JM9909645 *
M. I. IVANOVA ET AL: "Molecular basis for insulin fibril assembly", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 45, 10 November 2009 (2009-11-10), pages 18990 - 18995, XP055080001, ISSN: 0027-8424, DOI: 10.1073/pnas.0910080106 *
PHUONG TRAN ET AL: "Recombinant albumin: characterization as a pharmaceutical excipient in the stabilization of therapeutic protein products", 23 March 2010 (2010-03-23), XP055106166, Retrieved from the Internet <URL:http://www.biopharma.novozymes.com/en/information-centre/posters-and-presentations/Documents/Abdev10poster_phut_230310.pdf> [retrieved on 20140307] *
RODRIGUES ANANDA LAGES ET AL: "Does GLP-2 infusion reduce colon injury and improve protein nutritional status of piglets with colitis?", FASEB JOURNAL, vol. 25, April 2011 (2011-04-01), & EXPERIMENTAL BIOLOGY MEETING 2011; WASHINGTON, DC, USA; APRIL 09 -13, 2011, XP009177982 *
TUE RASMUSSEN ET AL: "The Molecular Chaperone Î+--Crystallin as an Excipient in an Insulin Formulation", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 27, no. 7, 24 March 2010 (2010-03-24), pages 1337 - 1347, XP019827960, ISSN: 1573-904X *

Also Published As

Publication number Publication date
WO2014096440A2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
WO2014096440A3 (en) Albumin composition for preventing and/or reducing formation of peptide fibrils
JOP20180103B1 (en) PHARMACEUTICAL COMPOSITION of CARBETOCIN
WO2015038796A3 (en) Secretion of heme-containing polypeptides
MX2015011898A (en) Pyrazolo compounds and uses thereof.
MX2021011906A (en) Delayed release compositions of linaclotide.
WO2015004533A3 (en) Novel substituted bicyclic compounds as bromodomain inhibitors
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
WO2014152157A8 (en) Methods and compositions for the generation and use of conformation-specific antibodies
WO2011130222A3 (en) Compositions and methods comprising variant proteases
EP2964246A4 (en) Surgical methods employing purified amphiphilic peptide compositions
WO2015120062A8 (en) Therapeutic compounds and compositions
WO2014145519A3 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
NZ706838A (en) Use of p3 of bacteriophage fusion proteins as amyloid binding agents
MX2014006337A (en) Use of p3 of bacteriophage as amyloid binding agents.
WO2015092810A3 (en) Amorphous form of idelalisib
WO2013072901A3 (en) Compositions and methods for treating glioma
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2014186450A3 (en) Highly potent inhibitors of porcupine
CN106687453A8 (en) As the tetrahydroquinoline derivative of bromine domain inhibitor
EP3046902A4 (en) Compositions for the treatment of hypertension and/or fibrosis
EP3046901A4 (en) Compositions for the treatment of hypertension and/or fibrosis
MX361233B (en) C-terminal hsp90 inhibitors.
CA2904166C (en) Formulations with reduced oxidation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13811982

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13811982

Country of ref document: EP

Kind code of ref document: A2